Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Total Valuation
Fate Therapeutics has a market cap or net worth of $105.93M. The enterprise value is $560.80K.
Market Cap$105.93M
Enterprise Value$560.80K
Share Statistics
Fate Therapeutics has 114.60M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding114.60M
Owned by Insiders18.11%
Owned by Instutions0.30%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -51.34%.
Return on Equity (ROE)-58.44%
Return on Assets (ROA)-42.27%
Return on Invested Capital (ROIC)-51.34%
Return on Capital Employed (ROCE)-52.29%
Revenue Per Employee$75,309.392
Profits Per Employee-$1,029,071.823
Employee Count181
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is -1.01. Fate Therapeutics’s PEG ratio is 0.00.
PE Ratio-1.01
PS Ratio13.76
PB Ratio0.59
Price to Fair Value0.59
Price to FCF-1.52
Price to Operating Cash Flow-1.53
PEG Ratio0.00
Income Statement
In the last 12 months, Fate Therapeutics had revenue of $13.63M and earned -$186.26M in profits. Earnings per share was -$1.65.
Revenue$13.63M
Gross Profit-$25.79M
Operating Income-$210.28M
Pretax Income-$186.26M
Net Income-$186.26M
EBITDA-181.18M
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was -$122.87M and capital expenditures -$730.00K, giving a free cash flow of -$123.60M billion.
Operating Cash Flow-$122.87M
Free Cash Flow-$123.60M
Free Cash Flow per Share-$1.08
Dividends & Yields
Fate Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-65.89%
Earnings Yield-99.30%
Stock Price Statistics
Beta3.00
52-Week Price Change-79.18%
50-Day Moving Average1.07
200-Day Moving Average2.48
Relative Strength Index (RSI)58.95
Average Volume (3m)2.09M
Important Dates
Fate Therapeutics upcoming earnings date is Apr 30, 2025, TBA.
Last Earnings DateMar 5, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
Fate Therapeutics as a current ratio of 7.58, with Debt / Equity ratio of 0.27
Current Ratio7.58
Quick Ratio7.58
Debt to Market Cap0.45
Net Debt to EBITDA-0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fate Therapeutics has paid $4.78M in taxes.
Income Tax$4.78M
Effective Tax Rate0.00%
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.92.
EV to Sales17.37
EV to EBITDA-1.34
EV to Free Cash Flow-1.92
EV to Operating Cash Flow-1.93
Balance Sheet
Fate Therapeutics has $279.07M in cash and marketable securities with $85.27M in debt, giving a net cash position of -$193.80M billion.
Cash & Marketable Securities$279.07M
Total Debt$85.27M
Net Cash-$193.80M
Net Cash Per Share-$1.69
Tangible Book Value Per Share$2.80
Margins
Gross margin is 100.00%, with operating margin of -1542.63%, and net profit margin of -1366.46%.
Gross Margin100.00%
Operating Margin-1542.63%
Pretax Margin-1366.46%
Net Profit Margin-1366.46%
EBITDA Margin-1295.41%
EBIT Margin-1434.52%
Analyst Forecast
The average price target for Fate Therapeutics is $6.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.17
Price Target Upside450.89%
Analyst ConsensusModerate Buy
Analyst Count12
Revenue Growth Forecast-78.55%
EPS Growth Forecast-0.92%